{"entity":{"id":"dm21-c-maytansinoid-system","kind":"term","name":"DM21-C peptide-linked maytansinoid system","aka":["DM21-C"],"tldr":"DM21-C is a peptide-linked maytansinoid system used in the investigational ADAM9-directed IMGC936 construct. Its attached component and released metabolites should be identified separately.","summary":"The IMGC936 preclinical report describes a DM21-C maytansinoid system with a cleavable tripeptide, site-specific conjugation and loading of approximately two. Earlier peer-reviewed chemical work studied peptide-cleavable self-immolative maytansinoids with different side chains and stereochemistry. That design family should not be collapsed into DM1 or DM4.\n\nA 2019 conference abstract reports DM51 as a major released catabolite of its DM21-C conjugates by LC-MS. That conference observation does not make DM51 an alias for the attached DM21-C system or identify every compound number in related papers. The IMGC936 phase 1/2 registry is completed and has posted results; no patient-benefit estimate is inferred here from the preclinical report or registry state.","asOf":"2026-11-09","links":[{"label":"IMGC936 with DM21-C: preclinical studies (2022)","url":"https://pubmed.ncbi.nlm.nih.gov/35511740/"},{"label":"Peptide-cleavable self-immolative maytansinoid conjugates (2019)","url":"https://pubmed.ncbi.nlm.nih.gov/31620224/"},{"label":"AACR 2019 abstract 538: DM21-C and DM51, conference evidence","url":"https://doi.org/10.1158/1538-7445.AM2019-538"},{"label":"IMGC936 registry NCT04622774, last update 15 January 2025","url":"https://clinicaltrials.gov/study/NCT04622774"}],"tags":[],"related":["bystander-effect","efflux-pump"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry","chemicalObservations":[{"sources":[{"label":"IMGC936 with DM21-C: preclinical studies (2022)","url":"https://pubmed.ncbi.nlm.nih.gov/35511740/"}],"checkedOn":"2026-11-09","species":{"name":"DM21-C linker-payload system"},"context":"IMGC936 preclinical design.","method":"Chemical design, cell assays, xenografts and nonhuman primate studies.","statement":"DM21-C is used with a cleavable tripeptide and site-specific conjugation in IMGC936.","evidenceType":"experimental","limitation":"The preclinical report does not establish patient benefit or a universal property of all maytansinoids.","property":"chemical-identity"},{"sources":[{"label":"AACR 2019 abstract 538: DM21-C and DM51","url":"https://doi.org/10.1158/1538-7445.AM2019-538"}],"checkedOn":"2026-11-09","species":{"name":"DM51"},"context":"Conjugates described in AACR 2019 abstract 538. This is conference evidence, not a patient outcome report.","method":"LC-MS identification of a major catabolite in the reported conjugate experiments.","statement":"The abstract identifies DM51 as a major released catabolite of its DM21-C conjugates.","evidenceType":"conference-abstract","limitation":"DM51 is not an alias for the attached DM21-C system. The Elicit DOI spelling resolved to a different canonical DOI in Crossref; that discrepancy is retained in the source receipt.","property":"release"},{"sources":[{"label":"IMGC936 with DM21-C: preclinical studies (2022)","url":"https://pubmed.ncbi.nlm.nih.gov/35511740/"}],"checkedOn":"2026-11-09","species":{"name":"DM21-C maytansinoid system"},"conjugate":{"name":"IMGC936"},"context":"The named IMGC936 product or preparation described by the source.","method":"Design and characterisation of the preclinical site-specific construct.","statement":"The preclinical report describes loading of approximately two.","evidenceType":"experimental","limitation":"This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.","property":"conjugate-loading"}]},"route":"/terms/dm21-c-maytansinoid-system/","neighbours":{"term":[{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/"},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/"},{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}